Scientists are poised to launch a phase 3 paediatric clinical trial of Chinese manufacturer Sinovac Biotech’s coronavirus vaccine in SA, as part of an international study that aims to evaluate the efficacy of two doses of the Coronavac shot. The research is an important step towards obtaining regulatory approval for paediatric use of the vaccine.

The SA Health Products Regulatory Authority has so far only granted Coronavac emergency use authorisation for adults aged between 18 and 59 years. The jab is, however, authorised in China for children as young as three years...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now